Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Headlines
Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care
2026.01.25
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
2026.01.25
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
2026.01.25
Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
2026.01.24
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
2026.01.23
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
2026.01.23
2025 Tianjin International Breast Cancer Conference | Prof. Jihui Hao: A Blueprint for Intelligent Breast Cancer Prevention and Care
2026.01.20
2025 Tianjin International Breast Cancer Conference | Prof. Zhongsheng Tong: Targeted Therapy Frontiers and the “Tianjin Experience”
2026.01.20
2025 Yat-sen Breast Cancer Conference | Prof. Qiang Liu: Advancing Multidisciplinary Care for Breast Cancer in China
2026.01.20
2025 Yat-sen Breast Cancer Conference丨Professor Jing Yao: Addressing the Multiple Unique Needs of Young Breast Cancer Patients and Optimizing Treatment Choices Through Patient-Centered Care
2026.01.20
Posted inUroStream

Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care

Posted by By Mourabit Halima 2026.01.25
Continue Reading
Posted inIOncology

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Posted by By Mourabit Halima 2026.01.25
Continue Reading
Immunotherapy for Locally Advanced Gastric Cancer: Current Landscape and Future Directions​

Immunotherapy for Locally Advanced Gastric Cancer: Current Landscape and Future Directions​

Posted by By Peng Geng 2025.07.02
Read More
Human Proteome Navigation Initiative

Human Proteome Navigation Initiative

Posted by By Peter W. PENG 2025.07.01
Read More
Organoids in Gastric Cell Differentiation and Drug Sensitivity Testing for Gastric Cancer

Organoids in Gastric Cell Differentiation and Drug Sensitivity Testing for Gastric Cancer

Posted by By Mourabit Halima 2025.07.01
Read More
Precision Therapeutics in Upper GI Cancers: Advances and Applications​

Precision Therapeutics in Upper GI Cancers: Advances and Applications​

Posted by By Lisa Cui 2025.07.01
Read More
ASCO | Professor Dickon Hayne Shares ANZUP 1301 Findings: Combined Mitomycin Intravesical Therapy May Help Alleviate BCG Shortage in High-Risk NMIBC

ASCO | Professor Dickon Hayne Shares ANZUP 1301 Findings: Combined Mitomycin Intravesical Therapy May Help Alleviate BCG Shortage in High-Risk NMIBC

Posted by By Mourabit Halima 2025.07.01
Editor’s note: Bacillus Calmette–Guérin (BCG) is the standard intravesical therapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC). However, in some countries and regions, BCG shortages remain a challenge, limiting…
Read More
Power of softness in mechano-onco-immunology

Power of softness in mechano-onco-immunology

Posted by By Mourabit Halima 2025.07.01
Read More
Tumor: A Special Metabolic Disease

Tumor: A Special Metabolic Disease

Posted by By Peng Longmei 2025.07.01
Read More
Experience in Precision Treatment of Esophageal Cancer

Experience in Precision Treatment of Esophageal Cancer

Posted by By Mourabit Halima 2025.07.01
Read More
Progress and Challenges of Novel Immunotherapy Targets

Progress and Challenges of Novel Immunotherapy Targets

Posted by By Mourabit Halima 2025.07.01
Read More
Following EMA Approval: Toripalimab Establishes New First-Line Standard for Esophageal Cancer

Following EMA Approval: Toripalimab Establishes New First-Line Standard for Esophageal Cancer

Posted by By Mourabit Halima 2025.07.01
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
  • Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    Post You Might Like
    Posted inUroStream
    Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care
    Posted by By Mourabit Halima 2026.01.25
    Posted inIOncology
    Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
    Posted by By Mourabit Halima 2026.01.25
    Posted inUroStream
    Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
    Posted by By Mourabit Halima 2026.01.25
    Posted inIOncology
    Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
    Posted by By Mourabit Halima 2026.01.24
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top

    Welcome to Mediamedic 👋
    It’s nice to meet you.

    Dive into a world of trusted health insights. Subscribe for monthly updates straight to your inbox

    Privacy is part of our care. No spam, just wellness.

    🔒 Privacy policy

    Check your inbox or spam folder to confirm your subscription.

    • Facebook
    • X (Twitter)
    • LinkedIn
    • More Networks
    Share via
    Facebook
    X (Twitter)
    LinkedIn
    Mix
    Email
    Print
    Copy Link
    Copy link
    CopyCopied